WO2008020087A1 - Sistema óptico implantable, procedimiento para su desarrollo y aplicaciones - Google Patents
Sistema óptico implantable, procedimiento para su desarrollo y aplicaciones Download PDFInfo
- Publication number
- WO2008020087A1 WO2008020087A1 PCT/ES2006/000467 ES2006000467W WO2008020087A1 WO 2008020087 A1 WO2008020087 A1 WO 2008020087A1 ES 2006000467 W ES2006000467 W ES 2006000467W WO 2008020087 A1 WO2008020087 A1 WO 2008020087A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optical system
- implantable optical
- cells
- annular
- implantable
- Prior art date
Links
- 230000003287 optical effect Effects 0.000 title claims abstract description 66
- 238000000034 method Methods 0.000 title claims abstract description 37
- 239000007943 implant Substances 0.000 claims abstract description 22
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 13
- 210000004102 animal cell Anatomy 0.000 claims abstract description 7
- 238000004873 anchoring Methods 0.000 claims abstract description 6
- 210000005260 human cell Anatomy 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 36
- 229920000642 polymer Polymers 0.000 claims description 29
- 239000000017 hydrogel Substances 0.000 claims description 22
- 239000013543 active substance Substances 0.000 claims description 14
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 238000011161 development Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000004005 microsphere Substances 0.000 claims description 8
- 229920001223 polyethylene glycol Polymers 0.000 claims description 8
- 238000013270 controlled release Methods 0.000 claims description 6
- 239000002077 nanosphere Substances 0.000 claims description 6
- 208000021921 corneal disease Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 125000004386 diacrylate group Chemical group 0.000 claims description 4
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 239000000178 monomer Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000003644 lens cell Anatomy 0.000 claims description 2
- 208000029515 lens disease Diseases 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 210000000651 myofibroblast Anatomy 0.000 claims description 2
- 238000000053 physical method Methods 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- 229920000671 polyethylene glycol diacrylate Polymers 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 230000010354 integration Effects 0.000 abstract description 6
- 208000022873 Ocular disease Diseases 0.000 abstract description 3
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 19
- 210000004087 cornea Anatomy 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 201000004569 Blindness Diseases 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 210000001508 eye Anatomy 0.000 description 7
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 238000002513 implantation Methods 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000030533 eye disease Diseases 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000029816 Collagenase Human genes 0.000 description 3
- 108060005980 Collagenase Proteins 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003999 initiator Substances 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 208000014733 refractive error Diseases 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- KWVGIHKZDCUPEU-UHFFFAOYSA-N 2,2-dimethoxy-2-phenylacetophenone Chemical compound C=1C=CC=CC=1C(OC)(OC)C(=O)C1=CC=CC=C1 KWVGIHKZDCUPEU-UHFFFAOYSA-N 0.000 description 1
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 206010015911 Eye burns Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 201000002287 Keratoconus Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001634 bornane-2,3-dione derivatives Chemical class 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 229920000891 common polymer Polymers 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 230000004453 corneal transparency Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- FAQJJMHZNSSFSM-UHFFFAOYSA-N phenylglyoxylic acid Chemical class OC(=O)C(=O)C1=CC=CC=C1 FAQJJMHZNSSFSM-UHFFFAOYSA-N 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036575 thermal burns Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/148—Implantation instruments specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/145—Corneal inlays, onlays, or lenses for refractive correction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Definitions
- the present invention has its field of application in the area of Ophthalmology. More specifically, this invention relates to an implantable optical system applied to corneal alterations, composed of a central optical part and a peripheral annular part comprising animal cells, which favors the integration of the implant into the patient's corneal tissue, as well as the method for obtaining it and its applications in eye disorders.
- corneal blindness Disorders that affect the cornea constitute one of the main causes of blindness worldwide, preceded in order of general importance only by cataracts.
- the epidemiology of corneal blindness is complicated and is accompanied by a variety of infectious and inflammatory eye diseases that cause corneal scars, which ultimately lead to blindness. Additionally, the prevalence of corneal diseases varies between different countries and even between different populations (1). Approximately 10 million people suffer corneal blindness worldwide (1, 3) due to both genetic and acquired conditions.
- corneal transplant The technique that has obtained the most successes in the face of these corneal complications is the corneal transplant, whose success depends fundamentally on the type of patient or recipient. Corneal transplantation is successful in approximately 90% in patients considered "low risk" in countries developed (1). These are characterized by loss of vision due to corneal scars due to trauma, keratoconus or endothelial failures (due to dystrophies or previous operations). Despite this high success rate of corneal transplantation in these patients, there are important limitations with the techniques currently used; these include graft failures due to immunological rejections or endothelial dysfunction, significant astigmatism due to topographic irregularity, unpredictability of refractive error, and other less common although problematic ones such as suture infections, recurrent corneal diseases, etc.
- corneal inflammatory diseases hereins simplex or zoster
- dry eye Sjogren syndrome
- severe and generalized superficial eye diseases e.g., scar pemfigoide eye, chemical / thermal burns, etc.
- certain congenital abnormalities eg Peter's disease
- Corneal blindness due to infection is endemic in many parts of the world; In developing countries, the situation worsens because they do not have eye banks (1, 2), postoperative medications or a social context necessary for routine postoperative check-ups.
- porous materials for the improvement of the integration between the core (lens or central part) and the skirt (ring that surrounds the core or annular part) and between the skirt and the receptor tissue
- porous materials include Teflon, Gore-Tex
- Biological and tissue engineering techniques allow us to use cells as authors in the reconstruction of tissues. These cells, isolated from their tissue and in the presence of a support (of a synthetic, natural or mixed nature), are capable of generating an extracellular matrix morphologically similar to that native and composed of collagens and other adhesive fibers (45).
- Hydrogels are good candidates for cell support. They are hydrophilic polymers that form three-dimensional networks with the ability to capture a lot of water without dissolving in it. They also exhibit good biocompatibility and high permeability to oxygen and other nutrients, being therefore materials of choice in cell therapy (38), tissue regeneration (39) and controlled release of active substances (65).
- the photoencapsulation technique in addition to cells and cellular components, allows other types of components to be encapsulated in these photopolymerizable materials (64). It allows encapsulating particles that act as active substance release systems, such as the micro and / or nanospheres consisting of biodegradable polymers that allow controlling the release of drugs effectively within the desired therapeutic range. Hubbel and his group proposed the technique of photopolymerization to form controlled release materials and systems (65).
- the controlled release systems of active substances have been used since the beginning of the 20th century (61) and were born due to the need to improve the administration of drugs. They are systems thanks to which the released dose can be controlled and systems capable of directing these active molecules specifically to target organs.
- the use of poly-DL-lactic acid and / or poly-D-lactic-co-glycolic acid has prevailed due to the total absence of toxicity of the degradation products and their modular degradation rate (62).
- the release of conventional active ingredients from polylactic / polyglycolic acid microspheres generally occurs by diffusion through the polymer matrix, as well as through the pores of the structure of the polymer. polymer.
- the biodegradation of the polymer matrix and dissolution of the degraded polymer continuously changes the geometry of the microspheres and the texture of the polymer matrix.
- the release model of active ingredients is a combination of diffusion and degradation.
- This keratoprosthesis is composed of an optical central part and another annular part (core and skirt).
- the main novelty is that the annular part, skirt, has cellular components capable of secreting collagen and proteoglycan fibers for a better integration of the implant and a maintenance of the corneal transparency and in that it has a system that doses chemical compounds directed to a particular function (for example anti-inflammatory substances, regenerators, etc.) creating a stabilizing microenvironment against the presence of the implant in the tissue.
- this bicompartmental lens can be adapted to the patient's requirements and will depend on the pathological state of the stroma and the corneal epithelium. Also, due to its characteristics, the implant can be used in the development of other types of implants in patients with ocular disorders of different nature.
- FIG. 1 General figure of the optical system seen in plane and in perspective.
- Fig. 2 Scheme of different types of implants.
- Ep Epithelium;
- It is a): Anterior stroma;
- It's m Medium stroma;
- It is p
- Posterior stroma Posterior stroma;
- Endothelium Endothelium.
- Fig. 3 Scheme of the process of obtaining biocompartmental lenses by photopolymerization.
- Stage 1) Preparation of the solution of the central optical part (SOL. A), which consists of a polymer solution (SP) and a photoinitiator (Fl);
- Stage 2) Preparation of the solution of the annular part or ring (SOL. B) composed of polymer solution (SP), photoinitiator (Fl), cells (C) and active spheres (E) as a therapeutic system;
- Stage 3) Deposition of solutions A and B from stages 1) and 2) respectively in specific molds; and
- Figure 4 Scheme of the photopolymerization stage for obtaining the biocompartmental lens. 1) Filling solutions A and B from phases 1 and 2 (figure 3) respectively; 2) Close the mold; 3) Polymerization and homogenization of the sample. 4) Opening of the lid and removal of the separator; 5) Closing the lid; 6) Polymerization and homogenization of the sample; 7) Opening of the lid and removal of the two compartment lens.
- the main object of the invention is to provide a new implantable optical system model formed by an optical central part and an annular anchor part with live animal cells, including humans. Another object of the invention relates to the method for obtaining said implantable optical system.
- the implantable optical system obtained by said method is also object of the invention.
- Another object of the invention contemplates the use of the implantable optical system in corneal and crystalline disorders, specifically in the development of corneal implants, such as intrastromal lenses or keratoprostheses, and intraocular lenses.
- the present invention provides a hybrid system composed of a mixture of synthetic materials with living materials, not biodegradable with biodegradable, inert substances with chemically active substances, combined in an implantable system that allows each of these compounds to perform their function.
- a main aspect of the invention contemplates an implantable optical system comprising an optical central part and an annular anchoring part comprising live animal cells, including human cells.
- the cells may come from the patient to be implanted and / or from a donor.
- These cells depending on the degree of ocular disorder and the objective to be repaired, can be selected from among stem cells, primary keratocytes, fibroblasts, myofibroblasts, cells of different origin susceptible to differentiation to stromal cell, genetically modified cells capable of exerting a regenerative effect , as well as lens cells.
- the cells incorporated in the ring are growing, proliferating and secreting components of the extracellular matrix forming interfibrillar bonds with other collagens and proteoglycans of the recipient tissue (of the patient) allowing 1) the subjection of the annular part to the host tissue and an improvement in the accommodation of the implant, which is particularly important since one of the most common causes of failure of the implants currently employed in the state of the art is the extrusion of the implant due to lack of implant-tissue adhesion and 2) a reparative effect on the part of living cells
- the annular anchoring part further comprises a therapeutic controlled-release system comprising one or more active substances of ophthalmic interest directed to a particular function (for example anti-inflammatory, antibiotics, antivirals, antitumor drugs, etc.) .
- this system can be micro and / or nano spheres, capsules or biodegradable micelles that encapsulate the active substances by means of different techniques.
- the material of the central part is preferably of synthetic and non-biodegradable origin, complying with the optical requirements of a lens and can be designed to correct different refractive errors (myopia, farsightedness, presbyopia).
- the material of the annular part acts as an element of attachment of the lens to the tissue and is a three-dimensional matrix capable of maintaining cells and other components in its interior and is preferably of synthetic or mixed origin and biodegradable or non-biodegradable.
- the material of both the central part and the annular part is a polymeric material.
- the components included in the annular anchoring part are immersed in said polymeric material.
- the polymeric material is of the hydrogel type.
- the polymerization mechanism of these hydrogels can be physical or chemical, ionic or covalent, driven by temperature changes, ionic changes, addition of bonding substances or radiation exposure.
- hydrogels can polymerize both in vivo and in vitro in the presence of photoinitiators using visible or ultraviolet light, converting a liquid monomer to gel.
- This type of hydrogels have advantages over other conventional polymerization techniques: control of space and time of the polymerization, short curing times (from less than a second to a few minutes) at ambient or physiological temperatures and a minimum heat production.
- Another great advantage of photopolymerization is that hydrogels can be created in situ from their aqueous precursors in a minimally invasive way, for example using laparoscopic devices, catheters or subcutaneous injections with transdermal illumination.
- photopolymerizable hydrogels have the advantage that they allow the photoencapsulation technique.
- This technique in turn has the great virtue that it allows the incorporation of the cells in the initial phase of the gelation process, that is to say, it allows mixing cells and polymers in the liquid phase, so that when the gelification of the material starts the cells They are incorporated inside.
- This is a great advantage for tissue engineering because it solves one of the limitations of this practice, which is the low effectiveness of adhesion by the cells to the materials in the initial phase of inoculation. This effectiveness is diminished when the support material is of porous matrix type, since the cells by simple weight and gravity fall without having the option to adhere to the material.
- the physical method of polymerization of the hydrogel used is photopolymerization, which allows the photoencapsulation technique to form a hybrid system that forms part of the biocomponent lens ring and in which the cells and The micro / nanoparticles responsible for the release are formed prior to photoencapsulation in the hydrogel.
- the photopolymerizable capacity of the hydrogels allows simultaneity in the processing of the material and the manufacturing of the implantable optical system.
- the annular and central part comprise at least one common hydrogel type macromer, preferably an acrylic derivative of polyethylene glycol, such as polyethylene glycol diacrylate
- the hydrogel type macromer may be copolymerizing other monomers / polymers in a differential manner in each part.
- the common polymers are soluble in water and have polymerizable zones, preferably by means of a photoinitiator that is activated under UV or visible radiation, and which polymerizes by radical polymerization.
- the possible polymerizable regions are acylates, diacrylates, oligoacrylates, methacrylates, dimethacrylates, oligomethacrylates or any other compound of biological origin sensitive to photopolymerization.
- unsaturated polymers derived from both synthetic polymers such as poly (ethylene oxide), poly (ethylene glycol), poly (vinyl alcohol), poly (vinyl pyrrolidone), poly (amino acids) or derivatives of natural compounds such as alginate, hyaluronic acid, chondroitin sulfate, keratan sulfate and chitosan. Or the copolymerization of both types of compounds, such as for example the copolymer of poly (ethylene glycol) and hyaluronic acid.
- the annular component can also be constituted by biodegradable polymers, said polymers have biodegradable regions, and preferably hydrolysable, such as, for example, the ester, peptide, anhydrides, orthoesters or phosphoester bonds.
- hydrolysis sensitive polymers are aliphatic polyesters such as polyglycolic acid (PGA) and its polylactic acid (PLA) copolymers and their copolymers, or polycaprolactone and its copolymers, polyhydroxybutyrates (PHB), polyphosphazenes, polyorthoesters and polycyanoacrylates.
- these may be of synthetic, semi-synthetic and / or natural origin.
- those of synthetic origin are those derived from poly (acrylic acid) and those derived from polyesters, mainly Ia polyepsiloncaprolactone, poly (lactic acid) and copolymers of lactic acid and glycolic acid.
- Other materials of semisynthetic origin are also used such as those cellulosic derivatives with different degrees of solubility, insoluble polymers such as ethyl celluloses and acetobutyrates of cellulose and pH-dependent solubility such as cellulose acetophthalates.
- polyesters are used to manufacture the release systems.
- Polyesters such as poly-D-lactic-co-glycolic acid and its derivatives, are particularly attractive for polymeric release controlled systems for their availability, biodegradability, non-toxicity, biocompatibility and for being easily combinable with a wide variety of active ingredients. .
- the interfacial polymerization, the emulsion and evaporation of the solvent and the atomization Preferably, the solvent emulsion and evaporation technique is used.
- anti-inflammatory drugs In relation to the active substances that are incorporated into the release system, anti-inflammatory drugs, antibiotics, antiviral drugs, antitumor drugs, etc. stand out mainly. of ophthalmic application. And others of more specific interest such as growth factors, growth factor inhibitors, other cytokines and inhibitors, etc. responsible for the corneal function.
- this therapeutic system directs the release of the active compound for the benefit of tissue repair in the implanted area.
- the release system is decomposing leaving gaps inside the base material of the ring, which are invaded by the cells and adhesive fibers of the matrix, enhancing the adhesive effect of said ring and favoring the integration of the implant in the stromal bed.
- composition of the annular part or ring can have three variants:
- Ring type 1 composed of cells encapsulated in the polymer solution
- the concentration of cells and spheres included in the annular part may vary depending on the design of the system, the size of the spheres, the load / release of the active substance, etc.
- the total solid mass of all the constituent components is comprised between 10 and 30% of the total volume of the formulation.
- preparation of a solution A comprising a polymer solution for the formation of the optical central part
- preparation of a solution B comprising a polymer solution and animal cells for the formation of the annular anchor part
- C deposition of solutions A and B independently in specific molds that have a separator
- removal of the separator and sealing of the central part with the annular part by polymerization to obtain a bicompartmental lens to.
- Preparations from stages a) and b) are deposited in specific and exclusive molds for each optical system.
- the design of the optical part depends fundamentally on the necessary refractive correction and the place of implantation of the lens, which also determines the design of the annular part ( Figure 2). Therefore, each lens will require a thickness and diameter of the specific optical and annular parts.
- the lens has a thickness of the optical part comprised between 100 and 600 ⁇ m, a thickness of the annular part between 100 and 300 ⁇ m and a total diameter of between 6 and 10 mm, of which 4 -6 mm correspond to the optical part and 2-4 mm to the annular part.
- solution B further comprises a therapeutic system capable of releasing one or more active substances in a controlled manner.
- polymer solutions A and B further comprise photoinitiators that are activated, in steps d) and e) with UV or visible light.
- photoinitiators that are activated, in steps d) and e) with UV or visible light.
- they have short decomposition times, they are at least partially soluble in water and preserve good biocompatibility with cellular compounds.
- the photoinitiators used in the photopolymerization are preferably of the type ⁇ -hydroxyketones, phenylglyoxylates, benzyl dimethyl ketals, alpha amino ketones, camphorquinones, such as, for example, 2-hydroxy-1- [4- (hydroxyethoxy) phenyl] -2-methyl-1 -propanone, or 2,2-dimethoxy-2-phenylacetophenone.
- the initiation of the polymerization is accompanied by a UV light radiation with a wavelength in the range of 320-900 nm, preferably between 350-370 nm.
- a UV light radiation with a wavelength in the range of 320-900 nm, preferably between 350-370 nm.
- the material from which the mold is manufactured, as well as its design must allow the passage of UV light so that the light curing takes place in adequate and constant conditions.
- Preferred materials are thermoplastic or thermoset polymeric materials, such as, for example, methyl polymethyl methacrylate polycarbonate, polyvinylchloride and inorganic glasses such as quartz with low or no UV light absorption
- the polymerization is carried out in two phases: a first one, where two pseudogels corresponding to the optical part and the annular part are obtained separately, and a second phase that, with the removal of this separator, both optic and annular pseudogels take contact. allowing the cross-linking and joining of both parts of the lens (Figure 4).
- the molds used can have:
- a mobile separator which can be manual or automatic and which may or may not be incorporated in the mold lid itself that allows light curing.
- the implantable optical system obtainable by the described procedure is contemplated.
- the implantable system of the present invention allows the personalization of the lens depending on the individual needs of each patient.
- compositions material, cells and active substances
- design in terms of shape, curvature, etc.
- the use of the implantable optical system described in corneal disorders is contemplated, specifically in the development of corneal implants, such as intrastromal lens, for correction of refractive defects for patients with healthy corneas; as implantation keratoprosthesis in the anterior stromal part for patients with defects in more superficial areas (epithelium and anterior stromal part) and as implantation keratoprosthesis in the posterior stromal part after epithelial and stroma trepanation for patients with complete stromal defects ( Figure 2).
- corneal implants such as intrastromal lens
- Example 1 The following is an example, without considering a limitation of an embodiment of the present invention: Example 1
- poly (ethylene glycol) diacrylate (PEGDA) of weight average molecular weight of 3400, was used in a weight / volume ratio of 10% in PBS.
- PEGDA poly (ethylene glycol) diacrylate
- 2- hydroxy ⁇ 1- [4- (hydroxyethoxy) phenyl] -2-methyl ⁇ 1-propanone was used, in a proportion of 0.05% weight / volume with respect to the polymer solution.
- the initiator solution was prepared just before its use in 70% ethanol, and kept on ice avoiding the incidence of light.
- the procedure for obtaining the base polymer solution of the annular part was performed similarly to that described in phase 1. However, since in this case the polymer solution receives cells, and to limit possible cytotoxicity effects, it was limited to add the initiator at the time of incorporation of the mixture into the mold for subsequent exposure to UV light.
- Biodegradable spheres loaded with an active substance were used as a therapeutic controlled release system. In this case, it was raised
- PLGA polylactic-glycolic acid
- dexamethasone steroidal anti-inflammatory widely used in ophthalmology
- dexamethasone internal organic phase
- dichloromethane aqueous external phase
- the organic / water (O / A) emulsion that was obtained was homogenized in a Polytron homogenizer at 5000 rpm for 2 minutes. Then the volume was completed by adding more aqueous phase and homogenized again at the same rate for 1 minute. Subsequently, this mixture was incorporated into an aqueous solution of greater volume (water and emulsifier) for 3-4 hours under stirring and at room temperature until complete evaporation of the solvent. The mature spheres were washed several times with distilled water. The granulometric fractions were separated by sieving. Finally they lyophilized for storage at 2-4 0 C under vacuum. Next, two different embodiments of this type of release system are described:
- the organic phase composed of 800 mg of 50:50 PLGA (inherent viscosity: 0.17-0.24 dL / g), 2ml of dichloromethane and 80-160 mg dexamethasone, was stirred for 1 minute and subjected to ultrasound keeping it on ice for another minute. This solution was added dropwise over an aqueous phase composed of 5ml of polyvinyl alcohol (PVA) to the
- the organic phase composed of 800 mg of 50:50 PLGA (inherent viscosity: 0.17-0.24 dL / g) in 15ml of dichloromethane and 200mg of dexamethasone dissolved in 15ml of acetone, this organic phase was stirred for 5 minutes and subsequently added dropwise on a 200 ml aqueous phase composed of 5% polyvinyl alcohol (Pm 72000).
- the emulsion was formed by ultrasounding it at 6OW for 10 minutes and keeping it on ice. Evaporation of the solvent was carried out by magnetic stirring for 12 hours at room temperature. Mature nanospheres were washed 3 times with distilled water and recovered by centrifugation at 35,000 rpm for 1 hour at 4 0 C. Finally lyophilized for storage at 2-4 0 C under vacuum.
- the area Prior to the enucleation of the eyes, the area was washed with iodized solution and saline.
- the cornea was removed using a scalpel (n ° 12) and collected in DMEM-F12 culture medium with an antibiotic solution composed of 1% penicillin and streptomycin keeping them on ice.
- the corneas were quartered and introduced into an enzymatic medium of collagenase (3.3 mg collagenase (SIGMA. Ref. C8176) in 1 ml of DMEM-F12) for 30-45 minutes at 142 rpm and at 37 0 C.
- collagenase 3.3 mg collagenase (SIGMA. Ref. C8176) in 1 ml of DMEM-F12
- a mixture composed of the polymeric solution of PEGDA containing the photoinitiator and PLGA spheres loaded with dexamethasone was prepared. After keeping this composition on a shaker for one minute, it was poured onto the cell pellet previously obtained after centrifugation of a keratocyte cell suspension for 10 minutes at 4 0 C.
- Samples were obtained with 80% constant aqueous content, and 20% solid matter composed of 10% PEGDA, 5% spheres (with a diameter between 500 nm and 100 ⁇ m) and 5% cells (with a diameter of approximately 20 ⁇ m).
- the bicompartmental lens thus obtained had a diameter of 7 mm (4 mm of central part and 3 mm of annular part) and a thickness of 0.200 mm.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2006/000467 WO2008020087A1 (es) | 2006-08-08 | 2006-08-08 | Sistema óptico implantable, procedimiento para su desarrollo y aplicaciones |
JP2009523308A JP2010500064A (ja) | 2006-08-08 | 2006-08-08 | 埋込み型光学システム、その開発および適用のための手順 |
CN2006800560365A CN101522133B (zh) | 2006-08-08 | 2006-08-08 | 可植入的光学系统,其开发和应用的方法 |
EP06807913A EP2052698A4 (en) | 2006-08-08 | 2006-08-08 | IMPLANTABLE OPTICAL SYSTEM, DEVELOPMENT METHOD AND APPLICATIONS |
US12/376,603 US20100215720A1 (en) | 2006-08-08 | 2006-08-08 | Implantable optical system, method for developing it and applications |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/ES2006/000467 WO2008020087A1 (es) | 2006-08-08 | 2006-08-08 | Sistema óptico implantable, procedimiento para su desarrollo y aplicaciones |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008020087A1 true WO2008020087A1 (es) | 2008-02-21 |
Family
ID=39081974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2006/000467 WO2008020087A1 (es) | 2006-08-08 | 2006-08-08 | Sistema óptico implantable, procedimiento para su desarrollo y aplicaciones |
Country Status (5)
Country | Link |
---|---|
US (1) | US20100215720A1 (es) |
EP (1) | EP2052698A4 (es) |
JP (1) | JP2010500064A (es) |
CN (1) | CN101522133B (es) |
WO (1) | WO2008020087A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2723588A1 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated uses |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US8469934B2 (en) * | 2010-01-27 | 2013-06-25 | Alcon Research, Ltd. | Pulsatile peri-corneal drug delivery device |
EP3427693B1 (en) * | 2010-09-30 | 2020-06-24 | KeraMed, Inc. | Reversibly deformable artificial cornea |
US10667903B2 (en) | 2013-01-15 | 2020-06-02 | Medicem Institute s.r.o. | Bioanalogic intraocular lens |
US10441676B2 (en) | 2013-01-15 | 2019-10-15 | Medicem Institute s.r.o. | Light-adjustable hydrogel and bioanalogic intraocular lens |
GB201519811D0 (en) * | 2015-11-10 | 2015-12-23 | Univ Belfast | Ocular compositions |
DE102017112085A1 (de) * | 2017-06-01 | 2018-12-06 | Carl Zeiss Meditec Ag | Künstliche Augenlinse mit darin ausgebildetem Medikamentendepot und Verfahren zum Herstellen einer künstlichen Augenlinse |
DE102017112087A1 (de) | 2017-06-01 | 2018-12-06 | Carl Zeiss Meditec Ag | Künstliche Augenlinse mit lasererzeugter doppelbrechender Struktur sowie Verfahren zum Herstellen einer künstlichen Augenlinse |
CN109265592B (zh) * | 2018-09-07 | 2020-08-07 | 清华大学深圳研究生院 | 具有高抗氧化性的角膜接触镜及其制备方法 |
CN109157305B (zh) * | 2018-09-25 | 2021-05-25 | 广州锐澄医疗技术有限公司 | 复合人工角膜及其制备方法 |
CN115671389B (zh) * | 2022-09-15 | 2024-01-30 | 北京航空航天大学 | 用于内皮移植的复合型人工角膜及其制备和使用方法 |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US4865601A (en) | 1987-07-07 | 1989-09-12 | Caldwell Delmar R | Intraocular prostheses |
EP0333344A2 (en) * | 1988-03-02 | 1989-09-20 | Minnesota Mining And Manufacturing Company | Corneal implants and manufacture and use thereof |
US4932968A (en) | 1987-07-07 | 1990-06-12 | Caldwell Delmar R | Intraocular prostheses |
EP0488401A1 (en) | 1990-11-30 | 1992-06-03 | Senju Pharmaceutical Co., Ltd. | A controlled-release pharmaceutical preparation for intra-ocular implant |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
US5282851A (en) | 1987-07-07 | 1994-02-01 | Jacob Labarre Jean | Intraocular prostheses |
US5300116A (en) | 1992-08-05 | 1994-04-05 | Lions Eye Institute Of Western Australia | Keratoprosthesis |
US5801033A (en) | 1992-02-28 | 1998-09-01 | The Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US20020091229A1 (en) | 1992-02-28 | 2002-07-11 | Board Of Regents, The University Of Texas System Texas | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US6645715B1 (en) | 1998-01-23 | 2003-11-11 | University Of Ottawa | Artificial cornea |
US20040136971A1 (en) | 2002-10-11 | 2004-07-15 | David Scharp | Implantation of encapsulated biological materials for treating diseases |
US20050080484A1 (en) | 2002-09-13 | 2005-04-14 | Ocular Sciences, Inc. | Devices and methods for improving vision |
US20050169962A1 (en) | 2002-07-12 | 2005-08-04 | Bhatia Sangeeta N. | Three dimensional cell patterned bioploymer scaffolds and method of making the same |
US20050244468A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20050281861A1 (en) | 2004-04-30 | 2005-12-22 | Allergan, Inc. | Macromolecule-containing sustained release intraocular implants and related methods |
WO2006028361A1 (es) | 2004-09-09 | 2006-03-16 | Arturo Jimenez Bayardo | Implantes y microesferas de liberación prolongada de fármacos de uso oftálmico y metodos para prepararlos |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH027954A (ja) * | 1988-03-04 | 1990-01-11 | Alcon Surgical Inc | 着色周辺部付きレンズの製造方法 |
JP3084309B2 (ja) * | 1991-10-31 | 2000-09-04 | 康博 小池 | 視力矯正用レンズの製造方法 |
DE19508922C2 (de) * | 1994-03-14 | 1999-10-14 | Norbert Schrage | Hornhautprothese |
AU726819B2 (en) * | 1996-03-29 | 2000-11-23 | Desmos, Inc. | Cellular attachment to laminin 5-coated trans-epithelial appliances |
JP3779801B2 (ja) * | 1997-09-12 | 2006-05-31 | 株式会社メニコン | 眼内レンズの製造方法 |
US6544286B1 (en) * | 2000-07-18 | 2003-04-08 | Tissue Engineering Refraction, Inc. | Pre-fabricated corneal tissue lens method of corneal overlay to correct vision |
SE0102543D0 (sv) * | 2001-07-16 | 2001-07-16 | Pharmacia Groningen Bv | Compositions capable of forming hydrogels in the eye |
ITPD20020064A1 (it) * | 2002-03-12 | 2003-09-12 | Fidia Advanced Biopolymers Srl | Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem |
JP2005532094A (ja) * | 2002-06-18 | 2005-10-27 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | 人工角膜 |
US20060287721A1 (en) * | 2004-10-05 | 2006-12-21 | David Myung | Artificial cornea |
-
2006
- 2006-08-08 JP JP2009523308A patent/JP2010500064A/ja active Pending
- 2006-08-08 CN CN2006800560365A patent/CN101522133B/zh not_active Expired - Fee Related
- 2006-08-08 WO PCT/ES2006/000467 patent/WO2008020087A1/es active Application Filing
- 2006-08-08 EP EP06807913A patent/EP2052698A4/en not_active Withdrawn
- 2006-08-08 US US12/376,603 patent/US20100215720A1/en not_active Abandoned
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
US4865601A (en) | 1987-07-07 | 1989-09-12 | Caldwell Delmar R | Intraocular prostheses |
US4932968A (en) | 1987-07-07 | 1990-06-12 | Caldwell Delmar R | Intraocular prostheses |
US5282851A (en) | 1987-07-07 | 1994-02-01 | Jacob Labarre Jean | Intraocular prostheses |
EP0333344A2 (en) * | 1988-03-02 | 1989-09-20 | Minnesota Mining And Manufacturing Company | Corneal implants and manufacture and use thereof |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
EP0488401A1 (en) | 1990-11-30 | 1992-06-03 | Senju Pharmaceutical Co., Ltd. | A controlled-release pharmaceutical preparation for intra-ocular implant |
US5801033A (en) | 1992-02-28 | 1998-09-01 | The Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US20020091229A1 (en) | 1992-02-28 | 2002-07-11 | Board Of Regents, The University Of Texas System Texas | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5458819A (en) | 1992-08-05 | 1995-10-17 | Lions Eye Institute Of Western Australia, Incorporated | Method of producing a keratoprosthesis |
US5300116A (en) | 1992-08-05 | 1994-04-05 | Lions Eye Institute Of Western Australia | Keratoprosthesis |
US6645715B1 (en) | 1998-01-23 | 2003-11-11 | University Of Ottawa | Artificial cornea |
US20050169962A1 (en) | 2002-07-12 | 2005-08-04 | Bhatia Sangeeta N. | Three dimensional cell patterned bioploymer scaffolds and method of making the same |
US20050080484A1 (en) | 2002-09-13 | 2005-04-14 | Ocular Sciences, Inc. | Devices and methods for improving vision |
US20040136971A1 (en) | 2002-10-11 | 2004-07-15 | David Scharp | Implantation of encapsulated biological materials for treating diseases |
US20050244468A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US20050281861A1 (en) | 2004-04-30 | 2005-12-22 | Allergan, Inc. | Macromolecule-containing sustained release intraocular implants and related methods |
WO2006028361A1 (es) | 2004-09-09 | 2006-03-16 | Arturo Jimenez Bayardo | Implantes y microesferas de liberación prolongada de fármacos de uso oftálmico y metodos para prepararlos |
Non-Patent Citations (72)
Title |
---|
AIKEN-O'NEILL, P.; M.J. MANNIS: "Summary of comeal transplant activity Eye Bank Association of America", CORNEA, vol. 21, no. 1, 2002, pages 1 - 3 |
ALHADLAQ A ET AL.: "Adult stem cell driven genesis of human-shaped articular condyle", ANNALS OF BIOMEDICAL ENGINEERING, vol. 32, no. 7, 2004, pages 911 - 923 |
AMERICA, E.B.A.O.: "Eye Bank Association of America", EYE BANKING STATISTICAL REPORT, 1999 |
BHATIA, S.N. ET AL., THREE DIMENSIONAL CELL PATTERNED BIOPOLYMER SCAFFOLDS AND METHOD OF MAKING THE SAME |
BRYANT, STEPHANIE J.; NUTTELMAN, CHARLES R.; ANSETH, KRISTI S.: "Cytocompatibility of UV and visible light photoinitiating systems on cultured NIH/3T3 fibroblasts in vitro", JOURNAL OF BIOMATERIALS SCIENCE POLYMER EDITION, vol. 11, no. 5, 2000 |
CALDWELL DELMAR, R. ET AL., INTRAOCULAR PROTESTS |
CALDWELL DR: "The soft keratoprosthesis", TRANS AM OPHTHALMOL SOC, vol. 95, 1997, pages 751 - 802 |
CARDONA H.: "Keratoprosthesis with a plastic fiber meshwork supporting plate. Report of an experimental and comparative histologic study", AM J OPHTHALMOL, vol. 64, no. 2, 1967, pages 228 - 233 |
CARLSSON, D.J. ET AL.: "Bioengineered corneas: how close are we?", CURR OPIN OPHTHALMOL, vol. 14, no. 4, 2003, pages 192 - 7 |
CHIRILA, T.V. ET AL., KERATOPROSTHESIS |
CHIRILA, T.V. ET AL., METHOD OF PRODUCING A KERATOPROSTHESIS |
CHIRILA, T.V.: "An overview of the development of artificial corneas with porous skirts and the use of PHEMA for such an application", BIOMATERIALS, vol. 22, 2001, pages 3311 - 3317 |
CRAWFORD GJ ET AL.: "Tissue interaction with hydrogel sponges implanted in the rabbit cornea", CORNEA, vol. 12, no. 4, 1993, pages 348 - 357 |
CRUISE, GREGORY M. ET AL.: "A sensitivity study of the key parameters in the interfacial photopolymerization of poly(ethylene glycol) diacrylate from porcine islets", BIOTECHNOLOGY AND BIOENGINEERING, vol. 57, no. 6, 1998, pages 655 - 665 |
CUKIERMAN, E. ET AL.: "Taking cell-matrix adhesions to the third dimension", SCIENCE, vol. 294, no. 5547, 2001, pages 1708 - 12 |
DOANE MG; DOHLMAN CH; BEARSE G: "Fabrication of a keratoprosthesis", CORNEA, vol. 15, no. 2, 1996, pages 179 - 184 |
DOHLMAN CH; TERADA H: "Keratoprosthesis in pemphigoid and Stevens-Johnson syndrome", ADV EXP MED BIOL, vol. 438, 1998, pages 1021 - 1025 |
DOHLMAN, C.: "A recollection from Boston", EXPERIMENTAL EYE RESEARCH, vol. 78, no. 3, 2004, pages XXI - XXII |
EDMAN P: "Methods of drug delivery", 1985, PERGAMON PRESS, article "Solid microspheres as drug delivery systems", pages: 23 |
ELISSEEFF J ET AL.: "Photoencapsulation of chondrocytes in poly(ethylene oxide)-based semi- interpenetrating networks", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 51, no. 2, 2000 |
ELISSEEFF, JENNIFER ET AL.: "Controlled-release of IGF-I and TGF-pl in a photopolymerizing hydrogel for cartilage tissue engineering", JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 19, no. 6, 2001, pages 1098 - 1104 |
GERMAIN, L. ET AL.: "Reconstructed human cornea produced in vitro by tissue engineering", PATHOBIOLOGY, vol. 67, no. 3, pages 140 - 7 |
GRIFFITH, M. ET AL., ARTIFICIAL CORNEA |
GRIFFITH, M. ET AL.: "Functional human corneal equivalents constructed from cell lines", SCIENCE, vol. 286, no. 5447, 1999, pages 2169 - 72 |
HICKS C ET AL.: "Development and clinical assessment of an artificial cornea", PROG RETIN EYE RES, vol. 19, no. 2, 2000, pages 149 - 170 |
HICKS CR ET AL.: "Clinical results of implantation of the Chirila keratoprosthesis in rabbits", BR J OPHTHALMOL, vol. 82, no. 1, 1998, pages 18 - 25 |
HICKS CR ET AL.: "Corneal replacement using a synthetic hydrogel cornea, AlphaCor: device, preliminary outcomes and complications", EYE, vol. 17, no. 3, 2003, pages 385 - 392 |
HICKS CR ET AL.: "Implantation of PHEMA keratoprostheses after alkali burns in rabbit eyes", CORNEA, vol. 17, no. 3, 1998, pages 301 - 308 |
HICKS CR ET AL.: "Keratoprostheses: advancing toward a true artificial cornea", SURV OPHTHALMOL, vol. 42, no. 2, 1997, pages 175 - 189 |
HICKS CR ET AL.: "Keratoprosthesis results in animals: an update", AUST N Z J OPHTHALMOL, no. 1, 1997, pages S50 - S52 |
HICKS CR ET AL.: "Keratoprosthesis: preliminary results of an artificial corneal button as a full-thickness implant in the rabbit model", AUST N Z J OPHTHALMOL, vol. 24, no. 3, 1996, pages 297 - 303 |
HICKS, C.R. ET AL.: "Outcomes of implantation of an artificial cornea alphacor: effects of prior ocular herpes simplex infection", CORNEA, vol. 21, no. 7, pages 685 - 690 |
HICKS, C.R.; G.J. CRAWFORD: "Melting after keratoprosthesis implantation: the effects of medroxyprogesterone", CORNEA, vol. 22, no. 6, 2003, pages 497 - 500 |
HILL-WEST JL ET AL.: "Inhibition of thrombosis and intimal thickening by in situ photopolymerization of thin hydrogel barriers", PROC NATL ACAD SCI U S A, vol. 91, no. 13, 1994, pages 5967 - 5971 |
HSIUE GH; LEE SD; CHANG PC: "Platelet adhesion and cellular interaction with poly(ethylene oxide) immobilized onto silicone rubber membrane surfaces", J BIOMATER SCI POLYM ED, vol. 7, no. 10, 1996, pages 839 - 855 |
HUANG GT ET AL., SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS |
HUBBEL JA ET AL., PHOTOPOLYMERIZABLE BIODEGRADABLE HYDROGELS AS TISSUE CONTACTION MATERIALS AS CONTROLLED-RELEASE CARRIERS |
HUBBEL JA. ET AL., GELS FOR ENCAPSULATION OF BIOLOGICAL MATERIALS |
HUGHES PM ET AL., MALONE ET AL. MACROMOLECULE-CONTAINING SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND RELATED METHODS |
JACOB-LABARRE, J., INTRAOCULAR PROTESTS |
JIMENEZ AM ET AL., IMPLANTS AND MICROSPHERES FOR THE SUSTAINED RELEASE OF DRUGS FOR OPHTHALMIC USE AND PREPARATION METHODS THEREOF |
JULIENNE MC ET AL.: "Preparation of poly (DL lactide/glycolide) nanoparticles of controlled particle size distribution: application of experimental designs", DRUG DEV IND PHARM, vol. 18, 1992, pages 1063 |
KHAN AO: "Visual sensation in cataract surgery", OPHTHALMOLOGY, vol. 108, no. 12, 2001, pages 2157 - 2158 |
LEE DA, DRUG DELIVERY DEVICE |
LEGEAIS JM ET AL.: "Keratoprosthesis with biocolonizable microporous fluorocarbon haptic. Preliminary results in a 24-patient study", ARCH OPHTHALMOL, vol. 113, no. 6, 1995, pages 757 - 763 |
LI, F. ET AL.: "Cellular and nerve regeneration within a biosynthetic extracellular matrix for corneal transplantation", PROC NATL ACAD SCI USA, vol. 100, no. 26, 2003, pages 15346 - 51 |
MARCHI V ET AL.: "Osteo-odonto-keratoprosthesis", CORNEA, vol. 13, no. 2, 1994, pages 125 - 130 |
MARMO JC; BACK A, DEVICE AND METHODS FOR IMPROVING VISION |
MASTERS, KRISTYN S. ET AL.: "Crosslinked hyaluronan scaffolds as a biologically active carrier for valvular interstitial cells", BIOMATERIALS, vol. 26, no. 15, 2005, pages 2517 - 2525 |
MILES-THOMAS J ET AL.: "Human stem cells in a photopolymerizable hydrogel: The next generation of engineered tissue", JOURNAL OF UROLOGY, vol. 171, no. 4, 2004, pages 46 |
NOURI M ET AL.: "Endophthalmitis after keratoprosthesis: incidence, bacterial causes, and risk factors", ARCH OPHTHALMOL, vol. 119, no. 4, 2001, pages 484 - 489 |
NUTTELMAN CR; TRIPODI MC; ANSETH KS: "Synthetic hydrogel niches that promote hMSC viability", MATRIX BIOLOGY, vol. 24, no. 3, 2005, pages 208 - 218 |
OHTORI A ET AL., CONTROLLED-RELEASE PHARMACEUTICAL PREPARATION FOR INTRA-OCULAR IMPLANT |
ORWIN, E.J.; A. HUBEL: "In vitro culture characteristics of corneal epithelial, endothelial, and keratocyte cells in a native collagen matrix", TISSUE ENG, vol. 6, no. 4, 2000, pages 307 - 19 |
PATTON, JAQUNDA N.; PALMER, ANDRE F.: "Photopolymerization of Bovine Hemoglobin Entrapped Nanoscale Hydrogel Particles within Liposomal Reactors for Use as an Artificial Blood Substitute", BIOMACROMOLECULES, vol. 6, no. 1, 2005, pages 414 - 424 |
PINTUCCI S ET AL.: "Influence of dacron tissue thickness on the performance of the Pintucci biointegrable keratoprosthesis: an in vitro and in vivo study", CORNEA, vol. 20, no. 6, 2001, pages 647 - 650 |
QUICK, DEBORAH J.; ANSETH, KRISTI S.: "DNA delivery from photocrosslinked PEG hydrogels: encapsulation efficiency, release profiles, and DNA quality", JOURNAL OF CONTROLLED RELEASE, vol. 96, no. 2, 28 April 2004 (2004-04-28), pages 341 - 351 |
QUINN CP ET AL.: "Photo-crosslinked copolymers of 2-hydroxyethyl methacrylate, poly(ethylene glycol) tetraacrylate and ethylene dimethacrylate for improving biocompatibility of biosensors", BIOMATERIALS, vol. 16, no. 5, 1995, pages 389 - 396 |
RAMAKUMAR, SANJAY ET AL.: "Howard Novel delivery of oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy model", JOURNAL OF UROLOGY, vol. 174, no. 3, September 2005 (2005-09-01), pages 1133 - 1136 |
RENARD G ET AL.: "Incorporation of a fluorocarbon polymer implanted at the posterior surface of the rabbit cornea", J BIOMED MATER RES, vol. 31, no. 2, 1996, pages 193 - 1999 |
RENARD G.: "Artificial cornea", BULL ACAD NATL MED, vol. 180, no. 3, 1996, pages 659 - 665 |
SANDEMAN SR ET AL.: "Novel materials to enhance keratoprosthesis integration", BR J OPHTHALMOL, vol. 84, no. 6, 2000, pages 640 - 644 |
SCHARP, D. ET AL., IMPLANTATION OF ENCAPSULATED BIOLOGICAL MATERIALS FOR TREATING DISEASES |
SCHNEIDER, A.I.; K. MAIER-REIF; T. GRAEVE: "Constructing an in vitro cornea from cultures of the three specific corneal cell types", IN VITRO CELL DEV BIOL ANIM, vol. 35, no. 9, 1999, pages 515 - 26 |
See also references of EP2052698A4 |
SHEN WU X: "Encyclopedic handbook of biomaterials and bioengineering", 1995, MARCEL DEKKER, article "Preparation, characterization, and drug delivery applications of microspheres based on biodegradable lactic/glycolic acid polymers", pages: 1151 - 200 |
TEICHMANN KD; AL HUSSAIN HM; KARCIOGLU ZA: "Long-term complications of Strampelli's osteo-odonto-keratoprosthesis", AUST N Z J OPHTHALMOL, vol. 24, no. 2, 1996, pages 158 - 159 |
WANG D ET AL.: "Bioresponsive phosphoester hydrogels for bone tissue engineering", TISSUE ENGINEERING, vol. 11, no. 1-2, 2005, pages 201 - 213 |
WEST JL; HUBBELL JA: "Separation of the arterial wall from blood contact using hydrogel barriers reduces intimal thickening after balloon injury in the rat: the roles of medial and luminal factors in arterial healing", PROC NATL ACAD SCI U S A, vol. 93, no. 23, 1996, pages 13188 - 13193 |
WHITCHER JP; SRINIVASAN M; UPADHYAY MP: "Corneal blindness: a global perspective", BULL WORLD HEALTH ORGAN, vol. 79, no. 3, 2001, pages 214 - 221 |
WILLIAMS CG ET AL.: "In Vitro Chondrogenesis of Bone Marrow-Derived Mesenchymal Stem Cells in a Photopolymerizing Hydrogel", TISSUE ENGINEERING, vol. 9, no. 4, 2003, pages 679 - 688 |
WONG VG, BIODEGRADABLE OCULAR IMPLANTS |
Also Published As
Publication number | Publication date |
---|---|
CN101522133A (zh) | 2009-09-02 |
JP2010500064A (ja) | 2010-01-07 |
EP2052698A4 (en) | 2010-01-06 |
CN101522133B (zh) | 2012-08-08 |
US20100215720A1 (en) | 2010-08-26 |
EP2052698A1 (en) | 2009-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008020087A1 (es) | Sistema óptico implantable, procedimiento para su desarrollo y aplicaciones | |
Khosravimelal et al. | Hydrogels as emerging materials for cornea wound healing | |
Mahdavi et al. | Bioengineering approaches for corneal regenerative medicine | |
Mobaraki et al. | Corneal repair and regeneration: current concepts and future directions | |
Trujillo-de Santiago et al. | Ocular adhesives: Design, chemistry, crosslinking mechanisms, and applications | |
Chen et al. | Biomaterials for corneal bioengineering | |
CA2848405C (en) | Fabrication of gelatin hydrogel sheet for the transplantation of corneal endothelium | |
Holland et al. | Artificial cornea: past, current, and future directions | |
Wang et al. | Decellularized porcine cornea-derived hydrogels for the regeneration of epithelium and stroma in focal corneal defects | |
Sun et al. | Construction and evaluation of collagen-based corneal grafts using polycaprolactone to improve tension stress | |
Lace et al. | Biomaterials for ocular reconstruction | |
Hancox et al. | The progress in corneal translational medicine | |
Lai et al. | Functional biomedical polymers for corneal regenerative medicine | |
CN107007879A (zh) | 一种活性人工角膜及其制备方法 | |
Li et al. | Applications of hydrogel materials in different types of corneal wounds | |
Prasathkumar et al. | The Design and Developments of Protein‐Polysaccharide Biomaterials for Corneal Tissue Engineering | |
Zheng et al. | Recent Advances in Ocular Therapy by Hydrogel Biomaterials | |
Jorge E et al. | In vivo Biocompatibility of Chitosan and Collagen–Vitrigel Membranes for Corneal Scaffolding: a Comparative Analysis | |
Griffith et al. | Corneal regenerative medicine: corneal substitutes for transplantation | |
Sasseville et al. | Biomaterials used for tissue engineering of barrier-forming cell monolayers in the eye | |
Lohchab et al. | Bridging the gap: The promise of corneal bioengineering and regeneration | |
Singh et al. | Tissue Engineering Therapies for Ocular Regeneration | |
Venugopal et al. | Stem cellebased therapeutic approaches toward corneal | |
Krishnaswami et al. | Functional biomaterials for corneal tissue regeneration | |
Venugopal et al. | Stem cell–based therapeutic approaches toward corneal regeneration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680056036.5 Country of ref document: CN |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06807913 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009523308 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006807913 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12376603 Country of ref document: US |